IMMP

#4131
Immutep Limited American Depositary Shares
0.54 USD
+74.19%
Sector: Atención Sanitaria
Básica: USD
Divisa de beneficio: USD
Rango diario
0.54
0.54
Rango anual
0.29
3.53
Cambio diario
+74.19%
Variación mensual
+10.20%
Variación en los últimos 6 meses
-75.00%
Cambio anual
-65.38%
Cierres anteriores
0.31
Abrir
0.54
Bid
Ask
Mínimo
0.54
High
0.54
Volumen
4
Ver el calendario completo

Financials

Visión general Informes Estadísticas
Trimestre Año
Informe de resultados Saldo Flujo de caja
Valor Q4, 24 TTM

Immutep Limited - American Depositary Shares

Immutep Ltd is a biotechnology company working primarily in the field of cancer immunotherapy using the LAG3 immune control mechanism. The company was originally built on CVac, a therapeutic cancer vaccine. In late 2014 the privately held French immunotherapy company Immutep SA was purchased by Prima Biotech. Prima currently has three main products in its pipeline, all acquired with Immutep: Eftilagimod alpha, which is recombinant soluble LAG-3, used as an activator of antigen presenting cells. This product has completed a Phase IIa clinical study, where it doubled the expected response rate in HER2-negative metastatic breast cancer. IMP731, a depleting monoclonal antibody for autoimmune diseases, targeting LAG-3+ activated T cells. This antibody has been licensed to GlaxoSmithKline. IMP701, an antagonist monoclonal antibody to LAG3 for use in cancer. This product has been licensed to Novartis.

Noticias